Genocea Biosciences Inc (NASDAQ:GNCA) Stock Falls 18% In a Week: Here is Why

January 3, 2022

Shares of Genocea Biosciences Inc (NASDAQ:GNCA) have been witnessing selling pressure over the past few sessions with a fall of 18% in a week. Trading Data On Friday, GNCA stock fell 2.52% to $1.16 with more than 415k shares, compared to its average volume of 535k shares. The stock has moved within a range of $1.1301 – 1.1940 after opening trade at $1.18.        Latest News Biopharmaceutical company developing next-generation neoantigen…

Read More >>

Genocea Biosciences Inc (NASDAQ: GNCA) Starts Phase I/IIa TiTAN study

July 15, 2021

Genocea Biosciences Inc (NASDAQ: GNCA) announced yesterday that it has kicked off phase I/IIa TiTAN study and has dosed its first patient. The study is meant for the investigation of T-cell therapy, which is a neoantigen-targeted therapy called GEN-011. The company underscored that the FDA has earlier accepted GEN-011’s NDA or new drug application for starting phase I/IIa study. The study was approved for patients who missed inhibitor therapy at…

Read More >>